Physician profile
Andrew Rogall
NPI 1689025710
$1,461.17
in general payments reported to CMS, 2019-2025
18 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.64 · 2020: $58.25 · 2021: $41.34 · 2022: $450 · 2023: $422 · 2024: $230 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $431.22 | 2021-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $245.63 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $126.15 | 2022-2023 | Jardiance, Mounjaro |
| Abbott Laboratories | $109.01 | 2022 | |
| Phathom Pharmaceuticals, INC. | $72.33 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.30 | 2020-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $63.10 | 2024-2025 | Breztri, Airsupra |
| Exact Sciences Corporation | $61.20 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $51.43 | 2022-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $50.50 | 2023-2025 | |
| Novo Nordisk INC | $48.85 | 2019-2024 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.68 | 2023 | Trulance, Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $27.99 | 2022 | |
| Amarin Pharma, INC. | $17.21 | 2022 | |
| Organon LLC | $16.02 | 2023 | Nexplanon |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $15.39 | 2022 | |
| Astellas Pharma US INC | $14.94 | 2023 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $13.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Rogall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.